Successful treatment of resistant SAPHO syndrome with anti-TNF therapy.

Abstract

A 42-year-old Caucasian woman with SAPHO syndrome (synovitis, acne, pustulosis, hyperostosis and osteitis) refractory to non-steroidal anti-inflammatory drugs, sulfasalzine, methotrexate, bisphosphonates and steroids was successfully treated with antitumour necrosis factor therapy (infliximab). This case was a diagnostic challenge leading to extensive investigations for infection and malignancy and delayed diagnosis for several years. We report the significant improvement in clinical, radiological and laboratory markers of disease activity on infliximab and the steroid sparing effect of such therapy.

• Authors: Shayma Lamya Hampton, Hazem Youssef
• Journal: BMJ case reports (BMJ Case Rep) Vol. 2013 (Jan 25 2013) ISSN: 1757-790X [Electronic] England
• PMID: 23355559 (Publication Type: Case Reports, Journal Article)

Chemical References

• Anti-Inflammatory Agents
• Anti-Inflammatory Agents, Non-Steroidal
• Antibodies, Monoclonal
• Tumor Necrosis Factor-alpha
• Prednisolone
• Infliximab

Topics

• Acquired Hyperostosis Syndrome (diagnosis, drug therapy)
• Adult
• Anti-Inflammatory Agents (therapeutic use)
• Anti-Inflammatory Agents, Non-Steroidal (therapeutic use)
• Antibodies, Monoclonal (therapeutic use)
• Drug Resistance
• Female
• Humans
• Infliximab
• Prednisolone (therapeutic use)
• Tumor Necrosis Factor-alpha (antagonists & inhibitors)